Kevin Ro, MD
Endocrinology · Los Altos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 15
- 3 carriers
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
15 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ro’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
15 of 15 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A140511 · Current
Licensed to practise in California · since 2016 · expires 2028-02-29 · David Geffen School of Medicine at UCLA.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$95,426
Medicare paid this office $95,426 for 266 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 218 | $51,416 | $110 |
| New patient visit (45+ min) | 86 | $10,243 | $119 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 206 | $5,865 | $15 |
| Long return visit (40+ min) | 21 | $4,116 | $158 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 14 | $1,112 | $29 |
Who their Medicare patients are
266 Original Medicare patients in 2024. Average age 76 · Women 71% · Also on Medicaid 7% · Health risk score 0.97. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 58% · Coronary heart disease 23% · Diabetes 22% · Cancer 19% · Chronic kidney disease 15% · Depression 13% · Atrial fibrillation 12% · Heart failure 8% · COPD 6%.
The office billed $337,948, Medicare allowed $131,928 and paid $95,426; for 4,507 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 266 | 4,507 | 76 | 0.97 | $337,948 | $95,426 |
| 2023 | 231 | 3,348 | 76 | 0.97 | $268,743 | $82,480 |
| 2022 | 364 | 3,335 | 74 | 1.11 | $274,643 | $91,647 |
| 2021 | 300 | 2,695 | 74 | 1.10 | $215,513 | $98,915 |
| 2020 | 206 | 1,991 | 74 | 1.30 | $176,370 | $69,131 |
| 2019 | 102 | 471 | 74 | 1.40 | $47,331 | $21,638 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 135 | $31,995 | $117 |
| New patient visit (45+ min) | 159 | $22,344 | $141 |
| New patient visit (60+ min) | 12 | $2,281 | $190 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 13 | $748 | $30 |
| Injection of drug or substance under skin or into muscle | 13 | $435 | $14 |
2022: 13 services
| Return visit (30+ min) | 209 | $31,144 | $96 |
| Injection, denosumab, 1 mg | 20 | $21,082 | None |
| New patient visit (45+ min) | 140 | $20,186 | $144 |
| Short return visit (20+ min) | 23 | $2,310 | $77 |
| Dxa bone density measurement of hip, pelvis, spine | 52 | $2,285 | $44 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 14 | $608 | $28 |
| Blood test, thyroid stimulating hormone (tsh) | 19 | $468 | $17 |
| Injection of drug or substance under skin or into muscle | 22 | $367 | $13 |
| Thyroxine (thyroid chemical), free | 16 | $242 | $9 |
| Blood test, comprehensive group of blood chemicals | 15 | $199 | $10 |
| Hemoglobin a1c level | 14 | $183 | $10 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 13 | $139 | $8 |
| Insertion of needle into vein for collection of blood sample | 23 | $104 | $3 |
2021: 13 services
| Return visit (30+ min) | 186 | $47,599 | $107 |
| Injection, denosumab, 1 mg | 19 | $28,281 | None |
| New patient visit (45+ min) | 73 | $10,634 | $146 |
| Dxa bone density measurement of hip, pelvis, spine | 90 | $4,053 | $45 |
| Short return visit (20+ min) | 21 | $1,648 | $78 |
| Blood test, thyroid stimulating hormone (tsh) | 16 | $521 | $17 |
| Injection of drug or substance under skin or into muscle | 19 | $349 | $12 |
| Blood test, comprehensive group of blood chemicals | 17 | $264 | $11 |
| Thyroxine (thyroid chemical), free | 14 | $253 | $9 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 17 | $218 | $8 |
| Blood test, lipids (cholesterol and triglycerides) | 11 | $201 | $13 |
| Hemoglobin a1c level | 11 | $146 | $10 |
| Insertion of needle into vein for collection of blood sample | 22 | $126 | $3 |
2020: 14 services
| Return visit (30+ min) | 137 | $32,153 | $91 |
| Injection, denosumab, 1 mg | 14 | $18,741 | None |
| New patient visit (45+ min) | 70 | $8,973 | $128 |
| Dxa bone density measurement of hip, pelvis, spine | 37 | $1,695 | $46 |
| Long return visit (40+ min) | 14 | $1,685 | $120 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 11 | $658 | $30 |
| Blood test, thyroid stimulating hormone (tsh) | 17 | $417 | $17 |
| Blood test, comprehensive group of blood chemicals | 14 | $241 | $10 |
| Injection of drug or substance under skin or into muscle | 14 | $230 | $11 |
| Thyroxine (thyroid chemical), free | 16 | $215 | $9 |
| Blood test, lipids (cholesterol and triglycerides) | 11 | $213 | $13 |
| Hemoglobin a1c level | 11 | $183 | $10 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 11 | $139 | $8 |
| Insertion of needle into vein for collection of blood sample | 27 | $122 | $3 |
2019: 2 services
| Return visit (30+ min) | 54 | $7,303 | $95 |
| New patient visit (45+ min) | 47 | $6,538 | $139 |
Drugs they prescribed that Part D paid
$386,910
Pharmacies billed $386,910 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 826) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
490 generic and 303 brand-name prescriptions · $386,910 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Forteo | 18 | $101,441 | $5,636 |
| Ozempic | 46 | $76,535 | $1,664 |
| Januvia | 41 | $64,592 | $1,575 |
| Jardiance | 25 | $41,400 | $1,656 |
| Tradjenta | 11 | $15,766 | $1,433 |
See all 17 drugs
| Forteo | 18 | $101,441 | $5,636 |
| Ozempic | 46 | $76,535 | $1,664 |
| Januvia | 41 | $64,592 | $1,575 |
| Jardiance | 25 | $41,400 | $1,656 |
| Tradjenta | 11 | $15,766 | $1,433 |
| Humalog Kwikpen U-100 | 16 | $5,282 | $330 |
| Synthroid | 33 | $3,844 | $116 |
| Nano 2nd Gen Pen Needle | 18 | $3,184 | $177 |
| Alendronate | 190 | $2,523 | $13 |
| Lantus Solostar | 13 | $2,377 | $183 |
| Levothyroxine | 139 | $1,773 | $13 |
| Risedronate | 24 | $1,749 | $73 |
| Glipizide Er | 67 | $822 | $12 |
| Ultra-Fine Original Pen Needle | 11 | $708 | $64 |
| Metformin Hcl Er | 35 | $562 | $16 |
| Metformin | 41 | $242 | $6 |
| Methimazole | 17 | $32 | $2 |
Year by year
| 2024 | 826 | 162 | 0% (0) | 37% | $386,910 |
| 2023 | 487 | 123 | 0% (0) | 41% | $256,812 |
| 2022 | 1,220 | 263 | 0% (0) | 44% | $457,840 |
| 2021 | 1,165 | 219 | 0% (0) | 48% | $449,520 |
| 2020 | 793 | 134 | 0% (0) | 58% | $289,947 |
| 2019 | 191 | 57 | 0% (0) | 54% | $63,699 |
| 2017 | 23 | 11 | None | None | $1,632 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Januvia | 30 | $50,121 | $1,671 |
| Jardiance | 17 | $31,410 | $1,848 |
| Ozempic | 22 | $30,875 | $1,403 |
| Tradjenta | 12 | $17,807 | $1,484 |
| Lantus Solostar | 17 | $11,699 | $688 |
| Testosterone | 11 | $8,711 | $792 |
| Levothyroxine | 86 | $1,440 | $17 |
| Alendronate | 87 | $1,428 | $16 |
| Glipizide Er | 33 | $888 | $27 |
| Ultra-Fine Original Pen Needle | 12 | $693 | $58 |
| Metformin | 27 | $349 | $13 |
| Metformin Hcl Er | 11 | $129 | $12 |
| Methimazole | 11 | $34 | $3 |
2022: 21 drugs
| Januvia | 64 | $78,657 | $1,229 |
| Lantus Solostar | 102 | $51,593 | $506 |
| Jardiance | 30 | $46,311 | $1,544 |
| Ozempic | 22 | $35,310 | $1,605 |
| Humalog Kwikpen U-100 | 38 | $29,252 | $770 |
| Trulicity | 16 | $25,190 | $1,574 |
| Victoza 3-Pak | 11 | $23,900 | $2,173 |
| Tradjenta | 16 | $22,173 | $1,386 |
| Novolog Flexpen | 22 | $20,270 | $921 |
| Basaglar Kwikpen U-100 | 19 | $10,266 | $540 |
| Insulin Lispro Kwikpen U-100 | 22 | $8,849 | $402 |
| Levothyroxine | 313 | $6,383 | $20 |
| Nano 2nd Gen Pen Needle | 59 | $4,779 | $81 |
| Synthroid | 49 | $4,314 | $88 |
| Glipizide Er | 89 | $1,852 | $21 |
| Ultra-Fine Nano Pen Needle | 15 | $1,731 | $115 |
| Droplet Pen Needle | 16 | $894 | $56 |
| Metformin | 80 | $831 | $10 |
| Metformin Hcl Er | 41 | $739 | $18 |
| Alendronate | 40 | $466 | $12 |
| Methimazole | 33 | $205 | $6 |
2021: 21 drugs
| Januvia | 74 | $74,709 | $1,010 |
| Humalog Kwikpen U-100 | 75 | $59,065 | $788 |
| Lantus Solostar | 87 | $46,257 | $532 |
| Forteo | 11 | $40,073 | $3,643 |
| Tradjenta | 37 | $39,936 | $1,079 |
| Victoza 3-Pak | 12 | $36,359 | $3,030 |
| Jardiance | 26 | $33,401 | $1,285 |
| Novolog Flexpen | 19 | $19,894 | $1,047 |
| Toujeo Solostar | 17 | $18,477 | $1,087 |
| Trulicity | 13 | $15,740 | $1,211 |
| Levothyroxine | 230 | $5,194 | $23 |
| Nano 2nd Gen Pen Needle | 55 | $4,709 | $86 |
| Synthroid | 58 | $4,573 | $79 |
| Ultra-Fine Nano Pen Needle | 27 | $2,907 | $108 |
| Glipizide Er | 81 | $1,487 | $18 |
| Metformin | 93 | $979 | $11 |
| Metformin Hcl Er | 44 | $948 | $22 |
| Droplet Pen Needle | 11 | $414 | $38 |
| Alendronate | 28 | $322 | $11 |
| Methimazole | 32 | $204 | $6 |
| Atorvastatin | 15 | $201 | $13 |
2020: 21 drugs
| Januvia | 68 | $59,105 | $869 |
| Humalog Kwikpen U-100 | 41 | $35,207 | $859 |
| Tradjenta | 45 | $28,979 | $644 |
| Lantus Solostar | 54 | $28,366 | $525 |
| Novolog Flexpen | 25 | $23,351 | $934 |
| Trulicity | 20 | $16,359 | $818 |
| Jardiance | 12 | $10,400 | $867 |
| Toujeo Solostar | 12 | $10,084 | $840 |
| Ultra-Fine Nano Pen Needle | 52 | $5,678 | $109 |
| Lantus | 12 | $5,027 | $419 |
| Basaglar Kwikpen U-100 | 15 | $3,890 | $259 |
| Insulin Lispro Kwikpen U-100 | 15 | $3,288 | $219 |
| Levothyroxine | 141 | $3,223 | $23 |
| Synthroid | 44 | $2,354 | $53 |
| Ultra-Fine Micro Pen Needle | 14 | $1,528 | $109 |
| Metformin | 55 | $614 | $11 |
| Metformin Hcl Er | 31 | $540 | $17 |
| Methimazole | 34 | $275 | $8 |
| Atorvastatin | 13 | $246 | $19 |
| Euthyrox | 11 | $120 | $11 |
| Glipizide Er | 14 | $109 | $8 |
2019: 7 drugs
| Humalog Kwikpen U-100 | 13 | $10,216 | $786 |
| Januvia | 11 | $7,286 | $662 |
| Tradjenta | 12 | $6,338 | $528 |
| Lantus Solostar | 13 | $3,990 | $307 |
| Ultra-Fine Nano Pen Needle | 16 | $1,425 | $89 |
| Levothyroxine | 27 | $514 | $19 |
| Metformin | 32 | $296 | $9 |
Money from drug and device companies
$51 in 2023
| 2023 | 2 | 2 | None | $51 |
| 2022 | 8 | 8 | None | $167 |
| 2021 | 7 | 11 | None | $196 |
| 2020 | 2 | 2 | None | $44 |
| 2019 | 3 | 3 | None | $54 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Corcept Therapeutics | Korlym | $37 | 1 payment
|
| Tolmar | Jatenzo | $14 | 1 payment
|
See all 2 published payments
| Tolmar | Meals · 2023-04-27 | Jatenzo | $14 |
| Corcept Therapeutics | Meals · 2023-03-06 | Korlym | $37 |
See earlier years (2022, 2021, 2020, 2019)
2022: $167
| Insulet | Omnipod | $25 | 1 payment
|
| Radius Health | Tymlos | $23 | 1 payment
|
| Abbvie | Synthroid | $22 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $21 | 1 payment
|
| Mannkind | Afrezza | $21 | 1 payment
|
| Regeneron Healthcare Solutions | Evkeeza | $20 | 1 payment
|
| Amgen | Evenity | $19 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $15 | 1 payment
|
2021: $196
| Bayer HealthCare Pharmaceuticals | Kerendia | $59 | 3 payments
|
| Novo Nordisk | Rybelsus | $37 | 2 payments
|
| Currax Pharmaceuticals | Contrave | $26 | 2 payments
|
| AbbVie | None | $22 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $19 | 1 payment
|
| Esperion Therapeutics | Nexletol | $18 | 1 payment
|
| Amgen | Evenity | $15 | 1 payment
|
2020: $44
| Radius Health | Tymlos | $27 | 1 payment
|
| Medtronic MiniMed | Minimed 670g System | $17 | 1 payment
|
2019: $54
| Amarin Pharma | Vascepa | $23 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $16 | 1 payment
|
| Regeneron Healthcare Solutions | Praluent | $15 | 1 payment
|
Professional record
- NPI
- 1477972628
- Licence
- CA A140511California A140511: Current · expires 2028-02-29
- Trained
- University of California, Geffen School of Medicine, 2014
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X); Student in a training program (390200000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2014-04-15
- NPI last updated
- 2022-09-02
- NPI record certified
- 2022-09-02
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 795 El Camino Real, Palo Alto, CA, 94301